معرفی
Dr Ruth Bawn is a researcher at Newcastle University specializing in the development of kinase inhibitors for anti-cancer therapy. Her work primarily focuses on extracellular signal-regulated kinase 5 (ERK5) and MDM2-p53 protein interactions, with significant contributions to high-throughput screening methodologies and structure-based drug design. Collaborations with colleagues like Professor Roger Griffin and Dr Ian Hardcastle demonstrate her interdisciplinary approach.
- Key Research Areas: ERK5 inhibition, MDM2-p53 targeting, kinase inhibitor development
- Expertise: Biochemistry, pharmacology, medicinal chemistry
Her publications (2014–2021) highlight advancements in:
- Orally bioavailable anti-cancer compounds
- Selectivity optimization over off-target kinases (p38α, BRD4)
- Hit validation and lead compound development
- Structure-activity relationship studies
While no formal awards are listed, her sustained publication record indicates ongoing impact in biochemical and pharmacological research domains.
۰مقاله ثبتشده